Lidocaine infusions for refractory chronic migraine: a retrospective analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35609890/
1 Anesthesiology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania, USA [email protected]. 2 Anesthesiology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania, USA. 3 Anesthesiology, Thomas...
Conclusion: Lidocaine infusions may be associated with short-term and medium-term pain relief in refractory chronic migraine. Prospective studies should confirm these results.
-
Amy Gonzales, Physician4yrThis is an interesting research as treating refractory migraine headache can be very challenging to the patient and the physician. I hope further studies can be done. I was Show More
-
Migraine Connect4yrKey Points • Source: Regional Anesthesia & Pain Medicine • Conclusion: “Lidocaine infusions may be associated with short-term and medium-term pain relief in refractory chronic migraine. Prospective studies should confirm these results.” • In this retrospective Show More
Long-term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35593783/
1 Department of Neurology, Danish Headache Center, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. 2 Geisel School of Medicine at Dartmouth, Hanover, New Hampshire,...
Conclusion: The long-term treatment with erenumab was well tolerated and showed sustained efficacy in patients with CM in whom prior preventive treatments had failed, with numerically greater treatment effects for 140 mg versus 70 mg.
Migraine monoclonal antibodies against CGRP change brain activity depending on ligand or receptor target - an fMRI study
Source : https://elifesciences.org/articles/77146
Clinical trial number: The basic science study was preregistered in the Open Science Framework ( https://osf.io/m2rc6). Editor's evaluation Antibodies to CGRP or to the CGRP receptor are now approved for...
Conclusions: These data suggest that despite relative impermeability of the blood-brain barrier for CGRP mAb, mAb treatment induces certain and highly specific brain effects which may be part of the mechanism of their efficacy in migraine treatment.
Brazilian descriptive study of 104 consecutive real-world migraine patients treated with monoclonal antibodies
Source : https://www.tandfonline.com/doi/abs/10.1080/00325481.2022.2080381?journalCode=ipgm20
Abstract Migraine is a highly disabling and prevalent neurological disorder. A peptide, calcitonin gene-related peptide, was identified as involved in migraine pathophysiology and monoclonal anti-CGRP antibodies have been developed. To...
Conclusions: This described analysis of migraine patients who used monoclonal antibodies presented one of the first Brazilian experiences with real-world patients. Our results may enlighten clinicians on the outcomes and ways of prescribing anti-CGRP antibodies.
Multisensory sensitivity differentiates between multiple chronic pain conditions and pain-free individuals - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35588150/
Multisensory sensitivity (MSS) to non-painful stimuli has been identified as a risk factor for the presence of coexisting chronic pain conditions (COPCs). However, it remains unclear whether MSS can differentiate...
Conclusion: Our findings support that MSS can differentiate between pain phenotypes with different degrees of expected central mechanism involvement, and also serves as a risk and resilience marker for total COPCs. This supports the use of MSS as a marker of heightened central nervous system processing, and thus may serve as a clinically...